Last reviewed · How we verify
NCT07349329
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
Phase 3 trial testing 608 in Axial Spondyloarthritis, Non-Radiographic in 380 participants. Not yet recruiting.
19 April 2028
Quick facts
| Lead sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 380 |
| Start date | 9 March 2026 |
| Primary completion | 19 April 2028 |
| Estimated completion | 21 February 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- 608
- Placebo
Conditions studied
- Axial Spondyloarthritis, Non-Radiographic — all drugs for Axial Spondyloarthritis, Non-Radiographic →
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Axial Spondyloarthritis, Non-Radiographic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of 608 in patients with nr-axSpA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07349329
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 608
Trials testing the same drug.
- NCT06222671 — A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) · Phase 2 · recruiting
- NCT04367441 — Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects · Phase 1 · unknown
Other Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. trials
Trials by the same sponsor.
- NCT07507513 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC · Phase 2 · not yet recruiting
- NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
- NCT07185269 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE · Phase 1, PHASE2 · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT07065136 — Evaluation of 627 in Healthy Adult Subjects · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07349329 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Last refreshed: 16 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07349329.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing